Cytokine gene-modified vaccines in the therapy of cancer
Language English Country Great Britain, England Media print
Document type Journal Article, Review
PubMed
8857300
DOI
10.1016/0163-7258(95)02016-0
PII: 0163725895020160
Knihovny.cz E-resources
- MeSH
- Cytokines adverse effects genetics therapeutic use MeSH
- Genetic Vectors MeSH
- Immunotherapy * MeSH
- Interferons biosynthesis therapeutic use MeSH
- Interleukins immunology therapeutic use MeSH
- Tumor Cells, Cultured MeSH
- Neoplasms pathology therapy MeSH
- Gene Transfer Techniques MeSH
- Tumor Necrosis Factor-alpha immunology therapeutic use MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Cytokines MeSH
- Interferons MeSH
- Interleukins MeSH
- Tumor Necrosis Factor-alpha MeSH
Therapeutic strategies based on the insertion of cytokine genes into the genome of tumour cells, followed by vaccination with the resulting genetically modified, cytokine-producing cells, represent a new potential prospect for treatment of cancer patients. In this review, the concept of cytokine gene-modified cancer vaccines is discussed; the discussion is focused on the rationale, characterization, progress in the development, preclinical testing, and first clinical trials. An effort is made to analyse and integrate the results obtained in different experimental model systems in order to determine the needed approaches and directions for further research.
References provided by Crossref.org
Local cytokine treatment of HPV16-associated tumours results in inhibition of their lung metastases